France-based SpineGuard announced its full-year 2015 financial results.
Here are nine facts:
1. SpineGuard's sales increased 43 percent to €6.3 million, up from €4.4 million in 2014.
2. In 2015, the company sold 7,449 PediGuard units, compared to 6,063 units in 2014.
4. Of the PediGuard units sold, the company sold 4,306 in the United States.
5. The gross margin reached 84.5 percent, compared to 85.2 percent the year prior.
6. SpineGuard's net loss was €3.9 million in 2015, compared to €4.5 million in 2014.
7. The company experienced a 13 percent increase in operating expenses, hitting €9.3 million.
8. Cash and cash equivalents registered at €3.2 million in 2015, compared to €2.5 million in 2014.
9. The company secured financing of €10.5 million.
Read SpineGuard's full financial report here.
"The strong growth in the USA, Europe and Japan, as well as the regulatory approval in China, continue to validate the outstanding clinical value of the PediGuard range," said Pierre Jérôme, CEO and co-founder, SpineGuard.